Your session is about to expire
← Back to Search
Pharmacokinetics of certolizumab pegol for Epidural Block (CHERISH Trial)
CHERISH Trial Summary
This trial will study the effects of certolizumab pegol, a drug used to treat chronic inflammatory diseases, during pregnancy.
- Epidural Block
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Crohn's Disease
- Ankylosing Spondylitis
- Plaque Psoriasis
CHERISH Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CHERISH Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the Federal Drug Administration issued a stamp of approval for Pharmacokinetics of certolizumab pegol?
"Our team's evaluation of certolizumab pegol's safety was a 1, as the medication is currently in Phase 1 clinical trials and has limited backing for both efficacy and safety."
Have previous experiments assessed the Pharmacokinetics of certolizumab pegol?
"Currently, 17 studies are actively researching the Pharmacokinetics of certolizumab pegol, with 4 trials in Phase 3. Shanghai is hosting many of these investigations but there are an additional 238 locations running trails for this pharmacological topic."
To what extent is this experiment being conducted on a global scale?
"At present, there are 4 medical centres taking part in this study. These facilities can be found in Oklahoma City, Houston and Minneapolis as well as one other city. To reduce the demands of travel for patients involved in this trial, it is advisable to choose a centre that is close by."
What therapeutic applications does certolizumab pegol typically serve?
"Certolizumab pegol is commonly used as a pharmacological agent to manage the symptoms of severe psoriatic arthritis, Crohn's disease, and other forms of rheumatoid inflammation."
What is the total sample size of this investigation?
"Regrettably, no more patients can be accepted into this trial as the last update was posted on September 15th 2022. However, 839 studies looking at rheumatoid arthritis and 17 related to pharmacokinetics of certolizumab pegol are actively recruiting participants if you're interested in other clinical trials."
Is enrollment still open for this research initiative?
"Per the official documents hosted on clinicaltrials.gov, recruitment for this medical study has already concluded. Initially posted in June 2020 and last updated September 2022, 856 other trials are currently open to new recruits instead."
Share this study with friends
Copy Link
Messenger